Skip to content

Mescaline research: what the evidence shows

A classic psychedelic phenethylamine found in several cacti and central to long-standing ceremonial traditions.

State of the evidence

Synthesized

Synthesized from 19 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Mescaline, peyote, san pedro, huachuma, then ranked by relevance.

Direct research on mescaline itself is sparse and mostly preclinical or observational. Human work shows mescaline reliably produces an acute psychotic-like state with visual effects and altered brain activity in small laboratory samples, while large population surveys find lifetime psychedelic use (including mescaline) is not linked to worse mental health, and one survey found mescaline/peyote use associated with lower opioid use disorder severity. Regular ceremonial peyote use showed no psychological or cognitive deficits, but samples are small, mostly cross-sectional, and no controlled clinical trials of mescaline as a treatment were identified.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 19 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. 1992 observational cohort 12 Mixed Mescaline produced an acute psychotic state with visual-system effects, right-hemisphere functional decrease, and a hyperfrontal SPECT pattern correlated with psychotic psychopathology.
Psychedelics and Mental Health: A Population Study 2013 cross-sectional survey 130152 No effect Lifetime psychedelic use, including mescaline, was not associated with increased rates of mental health outcomes and in some cases with lower rates.
Psychedelics not linked to mental health problems or suicidal behavior: A population study 2015 observational cohort 135095 No effect Lifetime psychedelic use was not significantly associated with past-year mental health problems, suicidal thoughts or attempts, depression, or anxiety.
Psychological and cognitive effects of long-term peyote use among Native Americans. 2005 observational cohort 176 No effect Regular ceremonial peyote use showed no significant psychological or cognitive deficits, and lifetime peyote use was not associated with neuropsychological performance.
Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health. 2026 cross-sectional survey with structural equation modeling 45133 Mixed Mescaline/peyote use was associated with lower opioid use disorder severity, whereas LSD/psilocybin/MDMA/DMT use was associated with higher severity, with the mescaline association present only in the high mental health impairment group.
Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats. 2026 pharmacological and resting-state fMRI in awake rats Mixed Mescaline produced cerebellar-selective BOLD suppression, global resting-state hyperconnectivity, abolished reward-related BOLD responses, and frequency-dependent acoustic gating effects.
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways 2017 review Supports Several effects of hallucinogens including mescaline involve agonist activity at the serotonin 5-HT2A receptor.
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. 2020 experimental study with dose-response experiments Supports Hallucinogen potency in the mouse head-twitch response correlated strongly with reported hallucinogenic potency in humans and with drug discrimination ED50 values in rats.
Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets 2026 theoretical or philosophical paper Unclear Argues that natural hallucinogens evolved primarily as ecological agents and that human psychoactivity is an evolutionary by-product of action on conserved neural targets, citing advances in mescaline biosynthesis in cacti.
Characterization Of Peyote Hybird Lophophora williamsii var Jourdaniana Through Genomic Analysis And Molecular Studies 2026 genomic and biochemical study Unclear The peyote accession has an allopolyploid genome with biased fractionation and unequal expression of mescaline biosynthetic enzymes, and immunolocalization suggests new sub-cellular enzyme locations.
NOVEL STRUCTURAL HYBRIDS OF MESCALINE WITH PCP-ANALOGS: POTENTIAL ANTAGONISTS FOR CENTRAL PCP-RECEPTORS 2026 theoretical or philosophical paper Unclear Proposes synthesizing structural hybrids of mescaline with PCP analogs to test potential antagonism at central PCP receptors, with no experimental data reported.
Schizophrenia: A New Approach. II. Result of a Year's Research 1954 theoretical or philosophical paper Unclear Proposes that a hypothetical 'M substance' with properties between mescaline and adrenaline may be an aetiological agent in schizophrenia.
Enzymatic Formation of Psychotomimetic Metabolites from Normally Occurring Compounds 1961 experimental study Supports An enzyme localized in rabbit lung N-methylates serotonin and tryptamine to psychotomimetic metabolites and also acts on phenylethylamine derivatives including mescaline.
Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids 2006 systematic review Supports Ritual oral DMT/harmala use has a safety margin comparable to codeine, mescaline, or methadone, with minimal dependence potential and risk of sustained psychological disturbance.
A Clinical and Metabolic Study of Acute Intoxication with Cannabis Sativa and its Role in the Model Psychoses 1958 clinical study Supports Oral cannabis produced mental disturbances similar to those caused by mescaline and lysergic acid, resembling schizophrenia symptoms and potentially serving as a research tool for psychoses.
Study of a New Schizophrenomimetic Drug—Sernyl 1959 review Mixed Presents opposing views on whether drug-induced model psychoses are useful for studying schizophrenia without stating a conclusion.
The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. 2026 narrative review Mixed Psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, though the magnitude of risk is inadequately quantified, while phenomenological and mechanistic distinctions suggest possible therapeutic uses in stable patients.
Sacred Medicine: Use of Psychogenic Peyote within Ho-Chunk Healing 2026 Historical analysis Supports Argues that a century of Native American Church peyote ceremony has served as religious expression and healing for cultural trauma and individual conditions such as PTSD, substance use, and depression.
magnetismo del peyote 2026 review Unclear Describes peyote botany, chemistry, medicinal qualities, ecology, archaeology, history, and religious practice, and discusses alarming scarcity and conservation efforts.

Points of agreement

  • Large population surveys find no association between lifetime psychedelic use, including mescaline, and worse mental health outcomes.
  • Observational data on regular ceremonial peyote use show no psychological or cognitive deficits.
  • Mescaline acts through serotonin 5-HT2A receptor agonism, consistent with other classical hallucinogens.
  • Human laboratory work shows mescaline acutely produces psychotic-like and perceptual alterations.

Conflicts

  • One survey found mescaline/peyote use associated with lower opioid use disorder severity while other psychedelics were associated with higher severity, diverging from the general null mental-health findings.
  • Historical model-psychosis literature disagrees on whether drug-induced states are valid models of schizophrenia.
  • Reviews on psychosis risk note that psychedelics may trigger psychosis in vulnerable individuals, whereas population surveys find no increased mental health problems at the group level.

Gaps

  • No controlled clinical trials of mescaline as a treatment were identified.
  • Human mescaline laboratory samples are very small and mostly acute or short-term.
  • Durability of any effects beyond acute dosing is largely unstudied for mescaline specifically.
  • Dose-response, blinding, and long-term safety data in humans are lacking.
  • Findings from ceremonial peyote users may not generalize to illicit or non-ritual mescaline use.
Browse these studies in the library

Common questions

What does the research agree on about mescaline?
  • Large population surveys find no association between lifetime psychedelic use, including mescaline, and worse mental health outcomes.
  • Observational data on regular ceremonial peyote use show no psychological or cognitive deficits.
  • Mescaline acts through serotonin 5-HT2A receptor agonism, consistent with other classical hallucinogens.
  • Human laboratory work shows mescaline acutely produces psychotic-like and perceptual alterations.
Where do studies on mescaline conflict?
  • One survey found mescaline/peyote use associated with lower opioid use disorder severity while other psychedelics were associated with higher severity, diverging from the general null mental-health findings.
  • Historical model-psychosis literature disagrees on whether drug-induced states are valid models of schizophrenia.
  • Reviews on psychosis risk note that psychedelics may trigger psychosis in vulnerable individuals, whereas population surveys find no increased mental health problems at the group level.
What is still unknown about mescaline?
  • No controlled clinical trials of mescaline as a treatment were identified.
  • Human mescaline laboratory samples are very small and mostly acute or short-term.
  • Durability of any effects beyond acute dosing is largely unstudied for mescaline specifically.
  • Dose-response, blinding, and long-term safety data in humans are lacking.
  • Findings from ceremonial peyote users may not generalize to illicit or non-ritual mescaline use.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Mescaline, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Mescaline or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: July 2026 →

963 articles · 153 from the last two years · 4,287,818 participants across 161 studies reporting sample size

Common study designs

review 188 systematic review 36 experimental study 106 historical analysis 77 theoretical or philosophical paper 101

Research volume by year

Compare topics →

266 studies whose primary subject is mescaline since 2003

Studies about mescaline per year, 2003 to 2026, peaking at 35 in 2023 Bar chart: one bar per year, taller where more studies were published that year. 0 20 40 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about mescaline per year, 2003 to 2026, peaking at 35 in 2023
Year Studies
2003 2
2004 6
2005 4
2006 4
2007 6
2008 2
2009 4
2010 5
2011 5
2012 10
2013 5
2014 8
2015 10
2016 12
2017 10
2018 9
2019 15
2020 12
2021 13
2022 27
2023 35
2024 24
2025 24
2026 14

Research

Synthesize the evidence → Search all →

Sacred Medicine: Use of Psychogenic Peyote within Ho-Chunk Healing

JORMA International Journal of Health and Social Sciences October 12, 2026 Michael Sersch

Current interest in the effectiveness of psychedelic-assisted recovery from trauma and other mental health conditions has been increasing. The Native American Church’s (NAC) use of the psychoactive plant peyote for over 100 years within sacred ritual has been a unique approach to religious expression and individual as well as collective healing, especially when addressing cultural trauma as...

DOI: 10.64074/4c3h8f90 (opens in new tab)

Arte Visionario con San Pedro y Ayahuasca en Ecuador, en diálogo con el mundo Kichwa

Proa Revista de Antropologia e Arte August 19, 2026 Susan Elizabeth Rocha

This research addresses visionary practices in contemporary Ecuadorian art, focusing on their relationship with the ritual ingestion of San Pedro (Echinopsis pachanoi) and Ayahuasca (Banisteriopsis caapi). From a perspective grounded in animist ontologies, which understand nature as a vast web of interconnected beings with interiority, the study analyzes how these master plants function as...

DOI: 10.20396/proa.v16i00.20719 (opens in new tab)

magnetismo del peyote

Revista de Arqueología Americana July 10, 2026 Stacy B. Schaefer

El peyote (Lophophora williamsii) es un cactus psicoactivo con una larga historia en el centro de las creencias religiosas, las prácticas curativas y el significado transformador que experimentan diversos pueblos indígenas de México y América del Norte. Los wixárika (indios huicholes) tienen la historia más larga conocida de uso continuo del peyote, mientras que las prácticas relacionadas con...

DOI: 10.35424/rearam.i44.6303 (opens in new tab)

NOVEL STRUCTURAL HYBRIDS OF MESCALINE WITH PCP-ANALOGS: POTENTIAL ANTAGONISTS FOR CENTRAL PCP-RECEPTORS

Bulletin of Pharmaceutical Sciences. Assiut University May 26, 2026 R. Shafik, N. Eshba, M. El-Semary et al.

The possible involvement of the synclinal conformation of mescaline with phencyclidine (PCP)-receptors has promoted the synthesis of certain novel structural hybrids of mescaline with PCP-analogs. The effect of mescaline and the potential antagonisticactivity of the newly proposed derivatives at central PCP-receptors of albino rat brains will await investigation. The suggested compounds were...

DOI: 10.21608/bfsa.1994.69795 (opens in new tab) Full text (opens in new tab)

Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats.

Neuroscience Bulletin May 21, 2026 Noah Cavallaro, Priya Rai, David Akins et al.

Mescaline, a 5-HT2A agonist psychedelic used ceremonially for millennia, lacks neuroimaging characterization due to its Schedule 1 status. Using pharmacological and resting-state fMRI in awake rats, we report mescaline's first comprehensive neurobiological profile. Acutely, mescaline produced cerebellar-selective BOLD suppression, suggesting functional disconnection from forebrain structures....

DOI: 10.1007/s12264-026-01632-3 (opens in new tab) Full text (opens in new tab) Cerebellum Fear Hippocampus Pharmacological MRI +1

Characterization Of Peyote Hybird Lophophora williamsii var Jourdaniana Through Genomic Analysis And Molecular Studies

Open Mind April 28, 2026 Ginny Li

Peyote cactus (Lophophora williamsii var. Jourdaniana) along with many other cacti can synthesize the hallucinogen, mescaline. They have recently garnered public attention after they re-emerged as a potential source as the new generation of mental health medications. Particularly since restrictions for psychoactive-based medication in research was relaxed in Canada. Despite the attention in...

DOI: 10.11575/prism/51381 (opens in new tab)

[Research Progress on Mescaline and Its Analogues].

Fa yi xue za zhi April 25, 2026 Ruidi Shen, Zhenhua Qian

The abuse of new psychoactive substances is severe globally. Among phenethylamine compounds, mescaline and its analogues are a class of substances that are often overlooked, yet their abuse has shown a gradual increase in recent years. This paper reviews mescaline and its analogues from three aspects: their basic information, pharmacological and toxicological properties, and detection methods....

DOI: 10.12116/j.issn.1004-5619.2024.340703 (opens in new tab) Full text (opens in new tab) Mescaline Detection method Forensic medicine New psychoactive substance +2

The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review

International Journal of Molecular Sciences March 28, 2026 Jonathan Shaw, Aidan Yong, Jacky Lee et al.

Mescaline, the primary bioactive alkaloid found in Peyote and San Pedro cactus, has been used in traditional medicine for centuries and is now attracting renewed interest for clinical applications. The purpose of this systematic review was to search the literature for studies reporting the use of mescaline to address the gap in our understanding of mescaline use and its impact. References were...

DOI: 10.3390/ijms27073081 (opens in new tab) Mescaline Alternative medicine Depression economics Systematic review +4

Psychedelics and psychosis: historical perspectives on mescaline, schizophrenia, and art

Zenodo (CERN European Organization for Nuclear Research) January 28, 2026 Irina Terekhova preprint

As early as the mid-nineteenth century, scientists hypothesized that psychedelics could serve as models for understanding psychosis. By the early twentieth century, this theory began to be tested experimentally. Since different types of psychotomimetic drugs induce qualitatively distinct forms of psychosis, there has been ongoing debate about whether there exist specifically ‘schizophrenogenic’...

DOI: 10.5281/zenodo.18401239 (opens in new tab) Mescaline Psilocybin Psychotomimetic Schizophrenia object-oriented programming +13

The first applications of mescaline in psychiatry: The case of Madame Louise Françoise R. and its contemporary relevance

Neuropharmacology October 15, 2025 Marion Hendrickx, Antoine Dampierre, Emmanuel Drouin 1 citation

At the beginning of the 20th century, while psychiatric knowledge remained limited, some physicians were already exploring innovative experimental paths. This article presents an unpublished clinical case of a patient, Madame Louise Françoise R., treated with mescaline in 1930 by Henri Claude and Henri Ey at Sainte-Anne in Paris, four years before their official publication on the subject. The...

DOI: 10.1016/j.neuropharm.2025.110707 (opens in new tab) Mescaline Ambivalence Perspective graphical Relevance law +5

Clinical trials

All Mescaline trials →